<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Influenza A virus</segment>
<segment id="3" parent="2" relname="elaboration">( IAV ) , a member of the Orthomyxoviridae family ,</segment>
<segment id="4" parent="1003" relname="same_unit">is a negative-sense , single-stranded , enveloped , segmented RNA virus .</segment>
<segment id="5" parent="1006" relname="span">IAV usually infects epithelial cells of the upper and lower respiratory tracts , including the nasal mucosa , trachea , and lungs ,</segment>
<segment id="6" parent="5" relname="elaboration">with no evident symptoms during the early phase of infection .</segment>
<segment id="7" parent="1007" relname="span">Once an influenza virus invasion occurs ,</segment>
<segment id="8" parent="1008" relname="joint">innate immunity is activated ,</segment>
<segment id="9" parent="1009" relname="span">and interferons are secreted by host cells</segment>
<segment id="10" parent="9" relname="purpose">to limit the early viral proliferation .</segment>
<segment id="11" parent="1011" relname="span">Then , adaptive immunity is activated by other cytokines</segment>
<segment id="12" parent="11" relname="elaboration">produced during viral infection .</segment>
<segment id="13" parent="1013" relname="span">However , in some cases , highly pathogenic influenza viruses induce cytokine storms , a consequence of excessive production of cytokines and interferon ,</segment>
<segment id="14" parent="13" relname="elaboration">resulting in infections and even death .</segment>
<segment id="15" parent="1016" relname="attribution">To facilitate virus replication in the host cells ,</segment>
<segment id="16" parent="1016" relname="span">IAV has evolved strategies</segment>
<segment id="17" parent="1017" relname="joint">to block the innate and adaptive immune responses of the host cells</segment>
<segment id="18" parent="1018" relname="span">and seize organelles from host cells</segment>
<segment id="19" parent="1019" relname="span">to synthesize a large number of metabolites</segment>
<segment id="20" parent="19" relname="elaboration">required for viral reproduction , as well as energy for the packaging of the virus .</segment>
<segment id="21" parent="1022" relname="span">Enveloped , non-enveloped , DNA and RNA viruses share lipid metabolites in their replication cycles</segment>
<segment id="22" parent="1023" relname="span">to induce the formation of new cytoplasmic membrane structures ,</segment>
<segment id="23" parent="22" relname="elaboration">which contribute to the replication and packaging of the viral genome .</segment>
<segment id="24" parent="1025" relname="span">Lipid metabolism also can block the innate immune response of host cells</segment>
<segment id="25" parent="24" relname="purpose">to ensure the large-scale replication of the virus .</segment>
<segment id="26" parent="1027" relname="joint">Therefore , IAV infection is linked closely to metabolism ,</segment>
<segment id="27" parent="1027" relname="joint">and the proliferation of the virus also is inseparable from the host metabolism .</segment>
<segment id="28" parent="1029" relname="span">This changing trend in small molecule metabolites may serve as a characterization of host – pathogen interactions</segment>
<segment id="29" parent="28" relname="purpose">to monitor immune status .</segment>
<segment id="30" parent="1031" relname="concession">Although significant progress has been made toward an anti-influenza virus drug discovery ,</segment>
<segment id="31" parent="1031" relname="joint">including M2 ion channel blockers , neuraminidase inhibitors , and polymerase inhibitors ,</segment>
<segment id="32" parent="1032" relname="span">challenges</segment>
<segment id="33" parent="32" relname="elaboration">posed by drug toxicity and viruses with genetic resistance remain a serious problem .</segment>
<segment id="34" parent="1035" relname="span">Previous research demonstrated the metabolic effects of influenza virus infection in Madin – Darby canine kidney</segment>
<segment id="35" parent="34" relname="restatement">( MDCK )</segment>
<segment id="36" parent="1036" relname="span">cells ,</segment>
<segment id="37" parent="36" relname="elaboration">displaying the intra- and extra-cellular metabolite profiling upon IAV infection .</segment>
<segment id="38" parent="1012" relname="joint">Little is known , however , about the systemic metabolic dynamics during the early stage of virus infection .</segment>
<segment id="39" parent="1039" relname="same_unit">During our study , we analyze changes in metabolism upon influenza virus infection in human cells during the first infectious cycle</segment>
<segment id="40" parent="1039" relname="same_unit">via metabolomics .</segment>
<segment id="41" parent="1012" relname="joint">Early metabolite analysis will throw new light on the activation of the innate immune metabolism .</segment>
<segment id="42" parent="1042" relname="attribution">We believe</segment>
<segment id="43" parent="1042" relname="joint">that the results of this work will elucidate the activation of innate immunity to viral infection from the perspective of the host</segment>
<segment id="44" parent="1042" relname="joint">and provide new control strategies for the development of novel drugs and the treatment and prevention of influenza virus infection .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1010" relname="background"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="span" parent="1003" relname="elaboration"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1006" relname="elaboration"/>
<group id="1008" type="multinuc" parent="7" relname="elaboration"/>
<group id="1009" type="span" parent="1008" relname="joint"/>
<group id="1010" type="multinuc" parent="1001" relname="span"/>
<group id="1011" type="span" parent="1010" relname="contrast"/>
<group id="1012" type="multinuc" parent="1010" relname="contrast"/>
<group id="1013" type="span" parent="1012" relname="joint"/>
<group id="1015" type="span" parent="1012" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="multinuc" parent="16" relname="purpose"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="span" parent="18" relname="purpose"/>
<group id="1022" type="span" parent="1012" relname="joint"/>
<group id="1023" type="span" parent="21" relname="purpose"/>
<group id="1024" type="span" parent="1012" relname="joint"/>
<group id="1025" type="span" parent="1024" relname="span"/>
<group id="1026" type="multinuc" parent="1025" relname="elaboration"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="1026" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="span"/>
<group id="1030" type="span" parent="1029" relname="elaboration"/>
<group id="1031" type="multinuc" parent="1030" relname="span"/>
<group id="1032" type="span" parent="1031" relname="joint"/>
<group id="1034" type="multinuc" parent="1012" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="span" parent="1034" relname="same_unit"/>
<group id="1039" type="multinuc" parent="1012" relname="joint"/>
<group id="1041" type="span" parent="1012" relname="joint"/>
<group id="1042" type="multinuc" parent="1041" relname="span"/>
	</body>
</rst>
